drugset / Trial / NCT04612413

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

NCT04612413

Phase 2 Completed 148 enrolled Enlivex Therapeutics Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Timeline

Start
2020-11-30
Primary completion
2024-01-12
Completion
2024-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Allocetra-OTS Cell therapy 5e+09 cells Intravenous
Subject Allocetra-OTS Cell therapy 1e+10 cells Intravenous